BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC

BioNTech SE BNTX has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc REGN to its FixVac candidate BNT116 combined with Libtayo (cemiplimab) in advanced non-small-cell lung cancer (NSCLC).
Under the terms of the agreement, the companies plan to jointly conduct clinical trials to evaluate the combination in different patient populations with advanced NSCLC and share development costs equally.
Regeneron and Sanofi SA SNY are jointly developing Libtayo.
The investigational mRNA-based cancer vaccine BNT116 is based on BioNTech's FixVac platform.
It consists of a fixed combination of shared tumor-associated antigens that were identified to be frequently expressed in NSCLC.
The companies plan to develop the collaboration beginning with Phase 1/2 clinical trials in the first-line treatment setting in advanced NSCLC.
Additionally, under a separate agreement, BioNTech plans to conduct and sponsor a Phase 1 LuCa-MERIT-1 trial evaluating the combination of BNT116 and Libtayo in further subpopulations with NSCLC.
Price Action: BNTX shares are down 1.35% at $124.55, REGN stock is down 0.68% at $614.38 during the market session on the last check Tuesday.